Immortalized Human Tracheal Epithelial Cells

Immortalized Human Tracheal Epithelial Cells are engineered from primary human tracheal epithelium to overcome the finite lifespan of native cells while preserving authentic airway epithelial characteristics. Through controlled immortalization—most commonly via human telomerase reverse transcriptase (hTERT) or SV40 Large T antigen—these cells acquire an extended replicative capacity without the gross chromosomal instability and loss of differentiation potential that plague tumor-derived lines.

A principal advantage lies in their retention of key epithelial phenotypes. These cells maintain classic cobblestone morphology and express definitive markers such as E-cadherin and cytokeratins, confirming their lineage fidelity. Critically, they remain fully compatible with air–liquid interface (ALI) culture systems, enabling differentiation into a pseudostratified mucociliary epithelium that recapitulates the barrier function, tight-junction architecture, and secretory physiology of the native human trachea in vivo. This capacity for physiological differentiation renders them markedly superior to standard cancer cell lines for modeling mucociliary clearance, tight-junction integrity, and host–pathogen interactions at the airway surface.

Furthermore, the unlimited proliferative potential of immortalized tracheal epithelial cells ensures experimental consistency and reproducibility across passages, eliminating the donor-to-donor variability and finite supply constraints inherent to primary cultures. Their robust adherence properties and defined growth requirements facilitate scalable expansion for high-throughput toxicology screening, respiratory disease modeling, and drug discovery applications.